Antiviral therapy for hepatitis C appears to be declining in the U.S.; lack of diagnosis is primary barrier to treatment

[Guest guest]

Antiviral therapy for hepatitis C appears to be declining in the U.S.; lack of diagnosis is primary barrier to treatment

23. November 2009 23:46

Researchers from the University of Michigan determined that only 663,000 of the approximately 3.9 million Americans with hepatitis C virus (HCV) infection received antiviral therapy between 2002 and 2007. Treatment rates appear to be declining, in part because only half of the patients know they are infected. If this disturbing trend continues, by 2030 less than 15% of liver-related deaths from HCV will be prevented by antiviral therapy.

more:

http://www.news-medical.net/news/20091123/Antiviral-therapy-for-hepatitis-C-appears-to-be-declining-in-the-US3b-lack-of-diagnosis-is-primary-barrier-to-treatment.aspx